Milrinone Lactate in Dextrose NDC 0143-9719

NDC codes

FDA NDC Directory

Product NDC (as listed)0143-9719Labeler and product segments. Claims need a package NDC.

Product NDC at billing width00143-9719Add the package segment from the table below.

Package NDCs as listed with the FDA, and the 11-digit 5-4-2 form used on claims. The highlighted digit is the added leading zero.
Package NDC	11-digit (billing)	Package	Copy
0143-9719-10	00143971910	10 CONTAINER in 1 PACKAGE (0143-9719-10) / 100 mL in 1 CONTAINER (0143-9719-01)Marketed from Jan 21, 2010

How the 11-digit form is made: The labeler segment has 4 digits, so one leading zero is added to it (4-4-2 → 5-4-2). Formatting the NDC does not by itself make it billable — the product, package and quantity must match what was dispensed or administered, and payer rules apply. Conversion rules

Product information

Brand name (proprietary): Milrinone Lactate in Dextrose
Generic name (nonproprietary): milrinone lactate in dextrose
Active ingredients: Milrinone lactate — 200 ug/mL
Dosage form: Injection, Solution
Route: Intravenous
Labeler: Hikma Pharmaceuticals USA Inc.
Product type: Prescription drug
Marketing category: ANDA — Abbreviated New Drug Application (generic)Application ANDA 090038
Marketing start: Jan 21, 2010
Listing expires: Dec 31, 2027
Other FDA classes: Phosphodiesterase 3 Inhibitors (Mechanism)
Identifiers: Product ID 0143-9719_e67caf04-0a9c-4638-90a6-c959c9e0b927SPL ID e67caf04-0a9c-4638-90a6-c959c9e0b927SPL set ID 4c2f052b-7ba2-4122-a50b-37ef2a834d61RxCUI 1791840, 1791842UNII 9K8XR81MO8
Pharmacologic class: Phosphodiesterase 3 Inhibitor

Billing references

What Med-Code can say about coding this product, and where each statement comes from. Nothing here is inferred from the name alone.

HCPCS codeNo match

No drug-specific HCPCS code in Med-Code's directory for this product. The directory is curated and not complete — check the current CMS HCPCS file before billing.

Administration

Drug administration (CPT 96360–96549)

When a clinician administers the drug, the administration is reported separately. Codes in this range cover hydration, therapeutic injections and infusions, and chemotherapy or other complex drug administration. The right code depends on route, duration and drug type, and self-administered drugs are not billed this way.

How CPT relates to drug billing

NDC on a medical claim

N400143971910 followed by a unit qualifier and the quantity

Package 00143-9719-10. Unit qualifiers: F2 (international unit), GR (gram), ME (milligram), ML (milliliter), UN (unit (each)). The qualifier and quantity depend on what was given. About the N4 qualifier

Product label

Current FDA label (SPL), effective May 18, 2026.

Indications (excerpt from the label)

INDICATIONS AND USAGE Milrinone lactate injection is indicated for the short-term intravenous treatment of patients with acute decompensated heart failure. Patients receiving milrinone should be observed closely with appropriate electrocardiographic equipment. The facility for immediate treatment of potential cardiac events, which may include life threatening ventricular arrhythmias, must be available. The majority of experience with intravenous milrinone has been in patients receiving digoxin and diuretics. There is no experience in controlled trials with infusions of milrinone for periods exceeding 48 hours.

Excerpt only. Read the full label for complete information.

Full label on DailyMed (opens in a new tab)

Other NDCs under ANDA 090038

Products listed under the same FDA application: other strengths and forms, and repackagers who relabel the same product.

FDA NDC Directory listings under ANDA 090038
Product	Strength	Form · route	Labeler	Product NDC
Milrinone Lactate in Dextrose	Milrinone lactate 200 ug/mL	Injection, SolutionIntravenous	Hikma Pharmaceuticals USA Inc.	0143-9718